Table 1.
Baseline characteristics for development and validation cohorts and for six-month survivors and non-survivors
| Variable | All patients (n = 1625) | Development (n = 844) | Validation (n = 781) | P -value | Survivors (n = 1085) | Non-survivors (n = 540) | P -value |
|---|---|---|---|---|---|---|---|
|
Age, years |
55 (38 to 66) |
56 (39–66) |
54 (36–66) |
0.288 |
52 (33–63) |
61 (49–80) |
<0.001 |
|
GCS |
|
|
|
|
|
|
|
| 3 to 6 |
828 (51) |
420 (50) |
408 (52) |
0.318 |
419 (39) |
409 (76) |
<0.001 |
| 7 to 13 |
797 (49) |
424 (50) |
373 (48) |
|
666 (61) |
131 (24) |
|
|
APACHE II |
22 (17 to 27) |
22 (17 to 22) |
22 (17 to 26) |
0.784 |
19 (15 to 23) |
27 (22 to 31) |
<0.001 |
|
SAPS II |
43 (31 to 55) |
43 (32 to 55) |
44 (31 to 55) |
0.988 |
38 (28 to 48) |
56 (45 to 63) |
<0.001 |
|
SOFA |
7 (5 to 10) |
7 (5 to 10) |
7 (5 to 10) |
0.744 |
7 (5 to 9) |
9 (7 to 11) |
<0.001 |
|
Length of stay, days |
|
|
|
|
|
|
|
| ICU |
2 (1 to 5) |
2 (1 to 5) |
2 (1 to 5) |
0.989 |
3 (1 to 6) |
2 (1 to 4) |
<0.001 |
| Hospital |
6 (3 to 12) |
6 (3 to 12) |
6 (3 to 13) |
0.457 |
7 (4 to 15) |
4 (1 to 8) |
<0.001 |
|
Mortality |
|
|
|
|
|
|
|
| ICU |
212 (13) |
107 (13) |
105 (13) |
0.647 |
NA |
212 (39) |
NA |
| Hospital |
346 (21) |
173 (21) |
173 (22) |
0.416 |
NA |
346 (64) |
NA |
| Six-month | 540 (33) | 278 (33) | 262 (34) | 0.795 | NA | 540 (100) | NA |
Categorical variables are presented as number (%), all continuous variables were highly skewed and are presented as median (IQR). APACHE II, acute physiology and chronic health evaluation II; SAPS II, simplified acute physiology score II; SOFA, sequential organ failure assessment; NA, not applicable.